Aytu Biopharma Inc
NASDAQ:AYTU
Aytu Biopharma Inc
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. The company is headquartered in Englewood, Colorado and currently employs 175 full-time employees. The company went IPO on 2017-10-20. The firm markets a portfolio of prescription products addressing primary care and pediatric markets. The firm's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. The company markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The firm's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. The company is headquartered in Englewood, Colorado and currently employs 175 full-time employees. The company went IPO on 2017-10-20. The firm markets a portfolio of prescription products addressing primary care and pediatric markets. The firm's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. The company markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The firm's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.
EXXUA Launch: Aytu has commercially launched EXXUA, the first FDA-approved 5HT1a agonist for major depressive disorder (MDD), with early prescription growth and positive patient feedback.
Early Momentum: Over 100 doctors across 27 states have prescribed EXXUA within just over a month of launch, with strong initial uptake even in areas without sales reps.
ADHD Portfolio: ADHD net revenue was $13.2 million, flat sequentially and only slightly down year-over-year, outperforming expectations despite generic competition.
Financials: Total net revenue for the quarter was $15.2 million, with a net loss of $10.6 million, driven by noncash warrant liability changes and increased EXXUA launch investment.
Pediatric Portfolio: Pediatric net revenue rebounded to $1.7 million from $715,000 last quarter, though this business remains noncore.
Guidance & Breakeven: Management expects EXXUA net revenue ramp will be modest in the near term due to early access programs, targeting breakeven at $17.3 million in quarterly net revenue.
Cost Discipline: EXXUA launch investment budget was cut from $10 million to under $8 million through efficiencies, with ongoing tight cost control.
